Global Cystic Fibrosis Therapeutics Market

Cystic Fibrosis Therapeutics Market Size, Share, Growth Analysis, By Drug Class(CFTR modulators, Mucolytics, Pancreatic enzyme supplements, and Bronchodilators), By Route of Administration(Oral drugs and Inhaled drugs), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35I2224 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 62 | Figures: 75

Cystic Fibrosis Therapeutics Market Insights

Cystic Fibrosis Therapeutics Market size was valued at USD 6.02 Billion in 2023 and is poised to grow from USD 6.83 Billion in 2024 to USD 18.81 Billion by 2032, growing at a CAGR of 13.50% during the forecast period (2025-2032).

One of the important factors boosting the demand for cystic fibrosis treatments during the forecast period is the rising prevalence of cystic fibrosis (CF) combined with the rising treatment rate. Furthermore, an increase in R&D financing by both private and governmental organizations, an increase in the number of projects performed by nonprofit organizations, and the availability of favorable reimbursement policies represent a few of the critical aspects projected to drive the marketplace in years to come.

Increased year-on-year patient growth results in increased demand for effective and efficient CF therapies. Cystic fibrosis Transmembrane Conductivity Regulator (CFTR) modulators, bronchodilators, mucolytic medications, anti-infective, antibiotics (oral, breathed in, or parents feeding formulae), anti-inflammatory medications, and pancreatic enzyme supplements are just a few of the readily accessible approved drug classes.

One of the critical aspects projected to drive market expansion is the increasing number of medication compositions in the pipelines of the leading players. Furthermore, a growing number of studies conducted to extend its target client base with its existing therapeutic portfolio is one of the market's drivers. Increasing R&D activities are projected to drive market expansion.

The presence of various charitable organizations such as CF Worldwide, Cystic Fibrosis Organization, Cystic Fibrosis Canada as well, South African Cystic Fibrosis confidence, and South African Cystic Fibrosis Organization, that are consistently involved in CF-related activities, is another important factor that can account for promoting growth of the cystic fibrosis therapeutics market. These organizations are investing large sums of money to find various therapies for CF and to assist major actors' research and development operations.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cystic Fibrosis Therapeutics Market size was valued at around USD 5.30 billion in 2022 and is expected to rise from USD 6.02 billion in 2023 to reach a value of USD 16.57 Billion by 2031, at a CAGR of 13.50% over the forecast period (2024-2031).

The cystic fibrosis therapeutics market competition consists of respiratory device manufacturers as well as standalone cystic fibrosis therapeutics producers. New technical advancements, such as the use of artificial intelligence, will generate growth prospects for new market entrants. For example, NuvoAir, a Swedish health care firm, created a digital platform that allows customers to perform at-home lung function tests. Companies are battling for market share, particularly in nations with advanced technology such as the United Kingdom, Germany, and the United States. Acquisitions and cooperation amongst market participants to strengthen their position have occurred. This is projected to increase market competition over the projection period. 'Vertex Pharmaceuticals Incorporated', 'AbbVie Inc.', 'Gilead Sciences, Inc.', 'Genentech, Inc.', 'Novartis AG', 'Teva Pharmaceutical Industries Ltd.', 'Mylan N.V.', 'Perrigo Company plc', 'Pharmaxis Ltd.', 'Celtaxsys, Inc.', 'Savara Inc.', 'Kamada Ltd.', 'Chiesi Farmaceutici S.p.A.', 'Galapagos NV', 'Proteostasis Therapeutics, Inc.', 'Eloxx Pharmaceuticals, Inc.', 'Insmed Incorporated', 'Arcturus Therapeutics Holdings Inc.', 'Translate Bio, Inc.', 'Zogenix, Inc.'

The primary driver of the cystic fibrosis therapeutics market is the increasing prevalence of cystic fibrosis, a genetic disorder that affects the respiratory, digestive, and reproductive systems. The disease is incurable and requires lifelong treatment, driving the demand for cystic fibrosis therapeutics.

Growing demand for personalized medicine: As the understanding of the genetic basis of cystic fibrosis improves, there is a growing demand for personalized medicine that targets the specific mutations responsible for the disease. This trend is expected to continue in the coming years, as newer therapies are developed that target specific mutations.

Asia Pacific had the largest cystic fibrosis market share in 2022 and is further expected to continue the same during the forecast period. The number of patients within the area is increasing and the urban lifestyle becomes more popular. This, together with increased healthcare spending, will most likely drive the APAC market. Furthermore, China's cystic fibrosis market had the highest market share, while India's cystic fibrosis market is the fastest expanding in the area.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cystic Fibrosis Therapeutics Market

Report ID: SQMIG35I2224

$5,300
BUY NOW GET FREE SAMPLE